This is not the first ADC-related acquisition for BMS this year as it builds its portfolio. Credit: Alpha Tauri 3D Graphics via www.shutterstock.com.

Bristol Myers Squibb (BMS) has signed another development deal focused on cancer therapeutics after acquiring the ORM-6151 programme from South Korean biotech Orum Therapeutics.

The agreement takes place less than a month after BMS’ high-profile acquisition of Mirati.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader to treat acute myeloid leukaemia (AML) and myelodysplastic syndromes. 

This acquisition validates Orum’s dual-precision targeted protein degradation approach, which involves the precision delivery of targeted protein degraders to cancer cells using antibody-drug conjugates (ADCs). The ORM-6151 programme is designed to target and degrade CD33, a protein found on the surface of certain cancer cells. 

BMS will pay an upfront amount of $100m, with the potential for milestone payments, taking the total deal value to $180m. 

Orum’s lead drug, called ORM-5029, is in Phase I clinical trials and targets HER2-expressing solid tumours in breast cancer patients. The company expects to complete the study in 2025. ADCs are targeted medicines that deliver chemotherapy agents to cancer cells. Rather than a toxin being used to target the cancer cells, Orum is using a small molecule designed to degrade target proteins. 

This is not the first ADC-related acquisition for BMS this year. In April, BMS gained exclusive rights to access the P5 conjugation platform from the Planegg, Germany-based Tubulis for the development of differentiated ADCs to treat cancer patients. The deal, which involved a $22.75m upfront payment, gave BMS sole responsibility for the development, production, and commercialisation of the resulting ADCs. 

According to GlobalData, the biopharmaceutical industry witnessed a 400% growth in total deal value of ADC-focused licensing agreements from 2017 to 2022 and reached a peak of $16.6bn in 2022. 

GlobalData is the parent company of Pharmaceutical Technology. 

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact